Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec:153:106846.
doi: 10.1016/j.ypmed.2021.106846. Epub 2021 Oct 13.

Prescription opioid use among women of reproductive age in the United States: NHANES, 2003-2018

Amanda L Elmore  1 , Omonefe O Omofuma  2 , Maria Sevoyan  2 , Chelsea Richard  2 , Jihong Liu  2
Affiliations

Prescription opioid use among women of reproductive age in the United States: NHANES, 2003-2018

Amanda L Elmore et al. Prev Med. 2021 Dec.

Abstract

Women are prescribed opioids more often than men. Prescription opioid use among women of reproductive age is a public health concern because opioid use during pregnancy is associated with decreased prenatal care and increased risk of adverse perinatal and maternal outcomes. Recent prevalence estimates and correlates of prescription opioid use and long-term use among women of reproductive age are limited. Using the 2003-2018 National Health and Nutrition Examination Survey (NHANES), we estimated the national prevalence, trend, and correlates of prescription opioid use, long-term use (≥ 90 days of use), and use of medications for opioid use disorder (MOUD) among women aged 15-44 (n = 13,558). Prescription opioid use within the last 30 days and prescription duration were collected through interviews and identified using prescription codes. Trend analysis was conducted using the National Cancer Institute Joinpoint Trend Analysis Software. The prevalence of prescription opioid use significantly decreased from 5.2% in 2003-2004 to 3.0% in 2017-2018 (p < .05). MOUD use increased significantly from 0.1% in 2005-2006 to 0.4% in 2011-2012. Long-term opioid use did not significantly change over time. Correlates of prescription opioid use and long-term use included ages 35-44, non-Hispanic White, public insurance, and women with poor or fair health status. As policy makers and clinicians strive to reduce the negative impacts of the opioid epidemic, they should consider the demographic groups most likely to use prescription opioids long-term. Additionally, reductions in opioid prescribing should be balanced with increased availability of nonopioid therapies and monitoring for opioid use disorder.

Keywords: Opioid use disorder; Prescription opioids; Reproductive health.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.. Prevalence (with 95% Confidence Interval) of Any Prescription Opioid Use Among Women of Reproductive Age, NHANES 2003-2018
2003-2004 through 2017-2018 PC = −9.16* (P value=0.01) *Indicates that the percentage change (PC) is significantly different from zero at the alpha=0.05 level
Fig 2.
Fig 2.. Prevalence (with 95% Confidence Interval) of Long-term Prescription Opioid Use Among Women of Reproductive Age, NHANES 2003-2018
2003-2004 through 2013-2014 PC = 2.55 (P value=0.56) 2013-2014 through 2017-2018 PC = −19.89 (P value=0.45) *Indicates that the percentage change (PC) is significantly different from zero at the alpha=0.05 level
Fig 3.
Fig 3.. Prevalence (with 95% Confidence Interval) of Medications for Opioid Use Disorder (MOUDs) Among Women of Reproductive Age, NHANES 2005-2018
2005-2006 through 2011-2012 PC = 129.68* (P value=0.03) 2011-2012 through 2017-2018 PC = −31.51 (P value=0.09) *Indicates that the percentage change (PC) is significantly different from zero at the alpha=0.05 level
See this image and copyright information in PMC

References

    1. Ailes EC, Dawson AL, Lind JN, Gilboa SM, Frey MT, Broussard CS, Honein MA, Centers for Disease, C., Prevention, 2015. Opioid prescription claims among women of reproductive age--United States, 2008-2012. MMWR Morb Mortal Wkly Rep 64:37–41. - PMC - PubMed
    1. Alderks CE, 2017. Trends in the Use of Methadone, Buprenorphine, and Extended-release Naltrexone at Substance Abuse Treatment Facilities: 2003-2015 (Update), The CBHSQ Report: August 22, 2017, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, MD. - PubMed
    1. Centers for Disease Control and Prevention, 2007. National Health and Nutrition Examination Survey, Data Documentation, Codebook, and Frequencies-1988-2018, https://wwwn.cdc.gov/Nchs/Nhanes/1999-2000/RXQ_DRUG.htm.
    1. Centers for Disease Control and Prevention, 2018. U.S. Opioid Prescribing Rate Maps.
    1. Centers for Disease Control and Prevention, 2019. 2019 Annual Surveillance Report of Drug-Related Risks and Outcomes — United States Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-rep....

Publication types

Substances